Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.
David Dalke
Advertisement
Articles by David Dalke
Advertisement
Latest Updated Articles
New Patent-Defense Path for PharmaOctober 1st 2014
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Onswik for Adults with Type 2 Diabetes
2
What Actually Went Wrong When a Phase 3 Trial Fails: Q&A with Dr. Remo Moomiaie-Qajar
3
From Experimentation to Execution: Strategic AI Adoption and Clinical Data Harmonization in Life Sciences
4
Nine European Drugmakers Warn the Continent Risks Losing the Pharma Investment Race: Report
5